Клинико-патогенетические особенности различных видов антисекреторной терапии у больных кислотозависимыми заболеваниями
При лечении больных рефлюкс-эзофагитом, А и В стадий целесообразно использовать препараты группы ингибиторов протонной помпы в удвоенных дозировках (омепразол 80 мг в сутки, лансопразол 120 мг в сутки, эзомепразол 80 мг в сутки). Более тяжелые С и О стадии рефлюкс-эзофагита требуют увеличения доз в три раза (омепразол 120 мг в сутки, лансопразол 180 мг в сутки). После наступления ремиссии… Читать ещё >
Содержание
- Глава 1. Пути улучшения результатов терапии больных кислото-зависимыми заболеваниями (обзор литературы)
- 1. Гастроэзофагеальная рефлюксная болезнь
- 2. Язвенная болезнь двенадцатиперстной кишки, ассоциированная с хеликобактерной инфекцией
- 3. Нарушения желудочно-кишечного тракта у пациентов, длительно принимающих нестероидные противовоспалительные препараты
- 4. Качество жизни у больных кислото-зависимыми заболеваниями
- Глава 2. Материалы и методы исследований '
- Глава 3. Сравнительная характеристика антисекреторного эффекта различных секретолитиков у больных язвенной болезнью двенадцатиперстной кишки
- Глава 4. Влияние наличия мутации генов цитохрома CYP2C19 на 95 эффективность монотерапии различными ингибиторами протонной помпы у больных рефлюкс-эзофагитом
- Глава 5. Влияние полиморфизма генов CYP2C19 на эффективность 102 антихеликобактерной терапии у больных язвенной болезнью двенадцатиперстной кишки: результаты открытого рандомизированного исследования
- Глава 6. Влияние полиморфизма генов IL-l?511 и TLR4 Asp299Gly 111 рецепторов на показатели результативности эрадикации Helicobacter pylori-инфекции у больных язвенной болезнью двенадцатиперстной кишки
- Глава 7. Профилактика рецидивов у больных после проведения 115 комплексного лечения осложнений язвенной болезни двенадцатиперстной кишки
Глава 8. Клиническая эффективность и безопасность длительной 123 терапии различными нестероидными противовоспалитель ными препаратами у больных остеоартритом в условиях профилактического применения ингибиторов протонной помпы
Глава 9. Роль кислотно-пептического фактора в генезе повреждений слизистой оболочки желудка при длительном приеме различных нестероидных противовоспалительных препаратов
Глава 10. Показатели клеточного обновления эпителия слизистой 145 оболочки желудка при длительном приеме различных нестероидных противовоспалительных препаратов и в условиях профилактического применения ингибиторов протонной помпы
Глава 11. Обсуждение
Выводы
Список литературы
- Авалуева Е.Б., Горшкова Е. В. Кислотообразующая функция желудка и антральный гастрит. // Рос. журн. гастроэнтерол., гепатол., колопроктол. 1996. — № 4. — С. 10.
- Алексеева A.B. Влияние диклофенака натрия и индометацина на показатели суточного мониторирования желудочной секреции у больных ревматоидным артритом. Дис. .канд. мед. наук. — М., 1999. -139 с.
- Алексеенко С.А. Клинико-патогенетические особенности различных видов фармакотерапии у больных с обострением язвенной болезни желудка и двенадцатиперстной кишки. Дис. .докт. мед. наук. -Хабаровск. — 1996. — 164 с.
- Аруин Л.И. Апоптоз при патологических процессах в органах пищеварения. // Клин. мед. 2000. — Т. 78, № 1. — С. 5−10.
- Аруин Л.И., Григорьев П. Я., Исаков В. А., Яковенко Э. П. Хронический гастрит. Амстердам. — 1993. — 362 с.
- Аруин Л.И., Капуллер Л. Л., Исаков В. А. Морфологическая диагностика болезней желудка и кишечника. М.: Триада-Х. — 1998. -483 с.
- Балаж А., Блажек И. Эндогенные ингибиторы клеточной пролиферации. М.: Мир. — 1982. — 304 с.
- Барышников А.О., Шишкин Ю. К. Программированная клеточная смерть (апоптоз). // Рос. онкол. журн. 1996. — № 1. — С. 58−61.
- Басхаева Р.Г. Клинико-морфологические исследования в процессе лечения больных язвенной болезнью двенадцатиперстной кишки, осложненной кровотечением Дис.. канд. мед. наук. — Москва, 2003. -145 с.
- Ю.Битги А. Д. Диагностические тесты в гастроэнтерологии. Пер. с англ. М.: Медицина. — 1995. — 224 с.
- П.Бобрышев Д. В. Роль нестероидных противовоспалительных препаратов в механизмах повреждения слизистой оболочки гастродуоденальной зоны Автореф. дис. .канд. мед. наук. -Ставрополь.- 1999. 21 с.
- Василенко В.Х., Гребенев А. Л., Шептулин A.A. Язвенная болезнь. (Современные представления о патогенезе, диагностике, лечении). -М.: Медицина. 1987. — 288 с.
- Геллер Л.И., Мамонтова М. И. Симптоматические гастродуоденальные язвы. Хабаровск. — 1978. — 113 с.
- Гланц С. Медико-биологическая статистика. М., Практика. — 1998.— 459 с.
- Григорьев П.Я., Яковенко Э. П. Клиническая гастроэнтерология. М., 2002, 578 с.
- Гринько A.B., Муравьев Ю. В. Состояние кислотообразующей функции желудка у больных ревматоидным артритом. Материалы Ш Российской гастроэнтерологической недели // Рос. журн. гастроэнтерол., гепатол., колопроктол. 1997. — № 5. — С. 23.
- Донцов В.И., Крутько В. Н., Подколзин A.A. Старение: механизмы и пути преодоления. М.: Биоинформсервис. 1997. — 122 с.
- Ивашкин В.Т., Комаров Ф. И., Рапопорт С. И. Краткое руководство по гастроэнтерологии. М. ООО «Издательский дом «М-Вести». — 2001.
- Ионова Т.И., Новик A.A., Сухонос В. А. Понятие качества жизни больных онкологического профиля. // Онкология. 2000. — т.2. — № 1−2.-С. 25−28.
- Исаков В.А. Ингибиторы протонного насоса: их свойства и применение в гастроэнтерологии. М.: ИКЦ «Академкнига», 2001. -304 с.
- Клинические лекции по гастроэнтерологии и гепатологии в 3-х томах под редакцией A.B. Калинина и А. И. Хазанова, М.: ГИУВ МО РФ. -ГВКГ им. H.H. Бурденко. 2002.
- Козак Н.П. Особенности поражений гепатобилиарной системы у больных остеоартрозом. // Украинский мед. вестник. 2000. — № 3. — С. 129−131.
- Колпакова Е.В. Качество жизни и артериальная гипертония: роль оценки качества жизни в клинических исследованиях и практической деятельности врача. // Тер. арх. 2000. — № 5. — С. 71−74.
- Колтунов С.С. Течение язвенной болезни двенадцатиперстной кишки при использовании различных видов противорецидивного лечения // Автореферат дис.. канд. мед. наук. Хабаровск, ДВГМУ. — 2000. -24 с.
- Крылов H.H., Кузин Н. М. К методике оценки результатов операций на желудке // Хирургия. 2000. — № 2. — С. 17 — 20.
- Курилович С.А., Решетников О. В. Эпидемиология заболеваний желудочно-кишечного трата. Новосибирск. — 2000. — 122 с.
- Мартынова Е.А. Молекулярные механизмы апоптоза. (Материалы Академической школы им. А. М. Уголева «Современные проблемы физиологии и патологии пищеварения». // Рос. журн. гастроэнтерол., гепатол., колопроктол. 1999. — № 6. — С. 75−83.
- Медик В.А., Токмачев М. С., Фишман Б. Б. Статистика в медицине и биологии: Руководство. Под ред. Ю. М. Комарова. Т. 1. Теоретическая статистика.— М.: Медицина. 2000. — 412 с.
- Насонов Е.Л. Специфические ингибиторы ЦОГ-2: решенные и нерешенные проблемы // Клин, фармакол. и тер. 2000. — № 9. — С. 57−64.
- Насонов Е.Л., Цветкова Е.С., Toe Н. Л. Селективные ингибиторы циклооксигензы-2: новые перспективы лечения заболеваний человека // Тер. арх. 1998. — № 5.- С. 8—14.
- Насонов Е.Л. Анальгетическая терапия в ревматологии: путешествие между Сциллой и Харибдой // Клин, фармакол. и тер.- 2003.- Т. 12, № 1.- С. 64−69.
- Насонов Е.Л. Интерлейкин-1 и его роль в патологии человека // Тер. архив. 1987, № 12. — С. 112−117.
- Насонов Е.Л. Нестероидные противовоспалительные препараты (Перспективы применения в медицине). — М.: Анко. 2000. — 262 с.
- Насонов Е.Л. Противовоспалительная терапия ревматических болезней.- М.: М-СИТИ. 1996. — 345 с.
- Насонов Е.Л. Специфические ингибиторы ЦОГ-2, решенные и нерешенные проблемы // Клин, фармакология и фармакотерапия. -2000.-Т. 9, № 1. С. 57−64.
- Насонов Е.Л. Целекоксиб первый специфический ингибитор циклооксигеназы-2 // РМЖ. — 1999. — Т. 7, № 10. — С. 1−5.
- Насонов Е.Л., Каратеев А. Е. Поражения желудка, связанные с приемом нестероидных противовоспалительных препаратов (часть I). // Клин, медицина. 2000. — № 3. — С. 4−10.
- Насонов Е.Л., Каратеев А. Е. Поражения желудка, связанные с приемом нестероидных противовоспалительных препаратов (часть П. // Клин, медицина. 2000. — № 4. — С. 11−15.
- Насонов Е.Л., Насонова В. А. Рациональная фармакотерапия ревматических болезней.- М.: ЬШегга, 2003. -507 с.
- Насонова В.А. Значение циклооксигеназы-2 в развитии боли. // Тер. арх. 2001. -№ 5.-56−57.
- Новик А.А. Оценка качества жизни в клинической медицине. // Клин, медицина. 2000. — № 2. — С. 47.
- Новик А.А., Ионова Т. Н., Шемеровская Т. Г. и др. Качество жизни больных ревматоидным артритом // Исследования качества жизни в медицине (Материалы Всероссийской конференции с международным участием. Санкт-Петербург. — 1999. — С. 108−111.
- Панцырев Ю.М., Сидоренко В. И., Чернякевич С. А., Бабкова И. В. Методические подходы к оценке отдаленных результатов хирургического лечения язвенной болезни // Хирургия. 1987. — № 11. -С. 22−29.
- Пасечников В.Д. // В кн.: Клинические лекции по гастроэнтерологии и гепатологии в 3-х томах под редакцией A.B. Калинина и А. И. Хазанова, М.: ГИУВ МО РФ- ГВКГ им. H.H. Бурденко, 2002
- Пиманов С.И. Эзофагит, гастрит, язвенная болезнь, М., Триада-Х, 2000.-421 с.
- Сидоренко C.B. Роль микробного фактора в этиологии и патогенезе сепсиса // Инфекции и антимикробная терапия. 2001. — № 3.
- Симаненков В.И., Захарова Н. В. Применение антисекреторных препаратов при кислото-зависимых заболеваниях // Гастроэнтерология Санкт-Петербурга. 2002. — № 4. — С. 30−32.
- Ушкалова Е.А., Шугурова И. М. Фармакогенетика ингибиторов протонной помпы // Фарматека. 2003. — № 7. — С. 35−40.
- Хомерики С.Г. Процессы регенерации в слизистой оболочке желудка и канцерогенез. // Росс. журн. гастроэнтерол, гепатол. и колопроктол. -2001. -№ 2. С. 17−23.
- Циммерман Я.С., Зинатулин М. Р. Концепция взаимоотношений организма человека и Helicobacter pylori. // Клин, медицина. 1999. -№ 2. — С.52−56.
- Цодиков Г. В. Механизм и диагностика повреждений желудка, возникающих при лечении противоревматическими препаратами (клинико-морфологическое и экспериментальное исследование. -Автореф. дисс. .канд. мед. наук. -М. 1978. — 18 с.
- Яковенко А.В. Суточное мониторирование интрагастральной кислотности при язвенной болезни двенадцатиперстной кишки как обоснование выбора антисекреторных препаратов. // Автореферат дис.. канд. мед. наук. Москва, РГМУ. — 1993. — С.32.
- Aalykke С., Lauritsen J.M., Hallas J. Helicobacter pylori and risk of ulcer bleeding among users of non-steroidal anti-inflammatory drugs: a case-control study. // Gastroenterology. 1999. — Vol. 116. — P. 1305−1309.
- Abelo A., Andersson T.B., Antonsson M. et al. Stereoselective metabolism of omeprazole by human cytochrome P450 enzymes. // Drug Metab Dispos. 2000. — Vol. 28, N 8. — P. 966−72.
- Adachi K., Katsube Т., Kawamura A. et al. CYP2C19 genotype status and intragastric pH during dosing with lansoprazole or rabeprazole. // Aliment Pharmacol Ther. 2000. Vol. 14, N 10. — P. 1259−66.
- Adithan C., Gerard N., Vasu S., Rosemary J. et al. Allele and genotype frequency of CYP2C19 in a Tamilian population. // Br. J. Clin. Pharmacol. 2003.-Vol. 56, N3.-P. 331−3.
- Alderman B.M., Cook G.A., Familari M. Resistance to apoptosis is a mechanism of adaptation of rat stomach to aspirin. // Am. J. Physiol. -2000. Vol. 278. — G839-G846.
- Alderman B.M., Yeomans N.D., Giraud A.S. Use of mRNA differential display to identify 3 genes involved in adaptation to injury in the stomach. // Gastroenterology. 2000. — Vol. 118. — A660.
- Alderman B.M., Giraud A.S., Yeomans N.D. Adaptation of the stomach to injury from non-steroidal anti-inflammatory drugs. // Curr. Gastroenterology Reports. 2001. — N 3. — P. 1−3.
- Ambulatory esophageal pH monitoring: practical approach and clinical applications / ed. by Richter J.E. Igaku-Shoin Medical Publishers. 1991. -229 p.
- Andersson T., Hassan-Alin M, Hasselgren G, Rohss K, Weidolf L. Pharmacokinetic studies with esomeprazole, the (S)-isomer of omeprazole. // Clin. Pharmacokinet. 2001. Vol. 40, N 6. — P. 411−26.
- Andersson T. Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole and pantoprazole. // Clin Pharmacokinet. 1996. Vol. 31, N 1. — P. 9−28.
- Aoyama N., Tanigawara Y., Kita T. et al. Sufficient effect of 1-week omeprazole and amoxicillin dual treatment for Helicobacter pylori eradication in cytochrome P450 2C19 poor metabolizers // J Gastroenterol. 1999. — Vol. 34, Suppl. 11. — P. 80−3.
- Aynacioglu A.S., Sachse C., Bozkurt A. et al. Low frequency of defective alleles of cytochrome P450 enzymes 2C19 and 2D6 in the Turkish population. // Clin Pharmacol Ther. 1999. — Vol. 66, N2. — P. 185−92.
- Balian J.D., Sukhova N., Harris J.W. et al. The hydroxylation of omeprazole correlates with S-mephenytoin metabolism: a population study // Clin Pharmacol Ther. 1995. — Vol. 57, N 6. — P. 662−9.
- Basci N.E., Bozkurt A., Kortunay S. et al. Proguanil metabolism in relation to S-mephenytoin oxidation in a Turkish population. // Br.J.lin Pharmacol. 1996.-Vol. 42, N. 6.-P. 771−3
- Bassotti G., Bucaneve G., Furno P. Double-blind, placebo-controlled study on effects of diclofenac sodium and indomethacin on postprandial gastric motility in man. // Dig. Dis. Sci. 1998. — Vol. 43, N 6. — P. 1172−6.
- Bathum L., Andersen-Ranberg K., Boldsen J. et al. Genotypes for the cytochrome P450 enzymes CYP2D6 and CYP2C19 in human longevity. Role of CYP2D6 and CYP2C19 in longevity. // Eur. J. Clin. Pharmacol. -1998.-Vol. 54, N5.-P. 427−30.
- Bathum L., Skjelbo E., Mutabingwa T.K. et al. Phenotypes and genotypes for CYP2D6 and CYP2C19 in a black Tanzanian population. // Br. J. Clin. Pharmacol. 1999. — Vol. 48, N 3. — P. 395−401.
- Bechi P., Balzi M., Becciolini A. Gastric cell proliferation kinetics & bile reflux after partial gastrectomy // Am. J. Gastroenterol. 1991. — Vol. 86, N10.-P. 1424−32.
- Beck I.T., Champion M.C., Lemire S. et al. The Second Canadian Consensus Conference on the Management of Patients with Gastroesophageal Reflux Disease. // Can. J. Gastroenterol. 1997. — Vol.11, Suppl B. P. 7−20.
- Bertz R.J., Granneman G.R. Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions // Clin. Pharmacokinet. 1997. — Vol. 32, N 3. — P. 210−58.
- Bianchi Porro G., Ardizzone S., Petrillo M. Endoscopic assessment of the effects of dipyronemetamizol in comparison to paracetamol and placebo on the gastric and duodenal mucosa of healthy adult volunteers // Digestion. -1996.-Vol. 57, N3.-P. 186−90.
- Bjarnason I., Hayllar J., MacPherson A.J., Russell A.S. Side effects of nonsteroidal anti-inflammatory drugs on the small and large intestine in humans // Gastroenterology. 1993. — Vol. 104, N 6. — P. 1832−47.
- Blaser M.J. Ecology of Helicobacter pylori in the human stomach. // J. Clin. Invest. 1997. — Vol. 100. — P.759−62.
- Blaser M.J. Linking Helicobacter pylori to gastric cancer. // Nat Med. -2000.-Vol. 6, N4.-P. 376−7.
- Bombardier C., Laine L., Reicin A. et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. // N. Engl. J. Med. 2000. — Vol. 343. — P. 1520−8.
- Borrelli F., Welsh N.J., Sigthorsson G. Gastric acid secretion in cyclooxygenase-1 deficient mice // Aliment. Pharmacol. Ther. 2000. -Vol. 14, N10.-P. 1365−70.
- Borsch G. Campylobacter pylori: new and rewened insights into gastritis-associated ulcer disease. // Hepato-gastroenterol. 1987. — Vol. 34. — P. 191−193.
- Bottiger Y., Tybring G., Gotharson E., Bertilsson L. Inhibition of the sulfoxidation of omeprazole by ketoconazole in poor and extensive metabolizers of S-mephenytoin // Clin. Pharmacol. Ther. 1997. — Vol. 62, N4.-P. 384−91.
- Bozina N., Granic P., Lalic Z. et al. Genetic polymorphisms of cytochromes P450: CYP2C9, CYP2C19, and CYP2D6 in Croatian population. // Croat. Med. J. 2003. — Vol. 44, N 4. — P. 425−8.
- Britzi M., Bialer M., Arcavi L. et al. Genetic polymorphism of CYP2D6 and CYP2C19 metabolism determined by phenotyping Israeli ethnic groups. // Ther. Drug Monit. 2000. — Vol. 22, N 5. — P. 510−6.
- Cahill R.J., Xia H., Kilgallen C. Effect of eradication of Helicobacter pylori infection on gastric epithelial cell proliferation. // Dig. Dis. Sci. -1995. Vol. 40, N 8. — P. 1627−1631.
- Carling L., Axelsson C.K., Forssell H. et al. Lansoprazole and omeprazole in the prevention of relapse of reflux oesophagitis: a long-term comparative study // Aliment. Pharmacol. Ther. 1998. — Vol. 12. — P. 98 590.
- Caselli M., LaCorte R., deCarlo L. Histological findings in gastric mucosa in patients treated with non-steroidal anti-inflammatory drugs // J. Clin. Pathol. 1995. — Vol. 48. — P. 553−5.
- Castell D.O., Kahrilas P.J., Richter J.E. et al. Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis // Am. J. Gastroenterol. 2002. — Vol. 97. — P. 575−583.
- Cattoretti G., Pileri S., Parravicini C. Antigen unmasking on formalin-fixed, parafin-embedded tissue sections // J. Pathol. 1993. — Vol. 171. — P. 83−98.
- Chan F.K., Sung J.J.Y., Chung S.C.S. Randomised trial of eradication of Helicobacter pylori before non-steroidal anti-inflammatory drug therapy to prevent peptic ulcers // Lancet. 1997. — Vol. 350. — P. 975−979.
- Chan F.K., To K.F., Wu J.C. Eradication of Helicobacter pylori and risk of peptic ulcers in patients starting long-term treatment with non-steroidal anti-inflammatory drugs: a randomised trial. // Lancet. 2002. — Vol. 359. -P. 9−13.
- Chang M., Dahl M.L., Tybring G. et al. Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish Caucasians: comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype. // Pharmacogenetics. 1995. — Vol. 5, N 6. — P. 358−63.
- Chang M., Tybring G., Dahl M.L. et al. Interphenotype differences in disposition and effect on gastrin levels of omeprazole suitability ofomeprazole as a probe for CYP2C19. // Br. J. Clin. Pharmacol. 1995. -Vol. 39, N5.-P. 511−8.
- Chau T.K., Marakami S., Kawai B. et al. Genotype analysis of the CYP2C19 gene in HCV-seropositive patients with cirrhosis and hepatocellular carcinoma // Life Sci. 2000. — Vol. 67, N 14. — P. 1719−24.
- Cheatum D.E., Arvanitakis C., Gumpel M. et al. An endoscopic study of gastroduodenal lesions induced by nonsteroidal anti-inflammatory drugs. // Clin. Ther. 1999. Vol. 21, N 6. — P. 992−1003.
- Chen A., Li C.N., Hsu P.I. et al. Risks of interleukin-1 genetic polymorphisms and Helicobacter pylori infection in the development of gastric cancer. // Aliment. Pharmacol. Ther. 2004. — Vol. 20, N 2. — P. 203−11.
- Chong E., Ensom M.H. Pharmacogenetics of the proton pump inhibitors: a systematic review. // Pharmacotherapy. 2003. Vol. 23, N 4. -P. 460−71
- Code C., Scholer J., Orvis A. Barrie offered by gastric mucosa to absorbtion of sodium. // Amer. J. Physiol. 1955. — Vol. 183. — P. 604−608.
- Collins F.S., Guttmacher A.E. Genetics moves into the medical mainstream. // JAMA. 2001. — Vol. 14 (286), N 18. — P. 2322−4.
- Courillon-Mallet A. Helicobacter pylori infection and gastric acid secretion // Gastroenterology. Clin. Biol. 1997. — Vol. 21, N 2. — P. 13 946.
- Cryer B., Dubois A. The advent of highly selective inhibitors of cyclooxygenase~a review. // Prostaglandins Other Lipid Mediat. 1998. -Vol. 56, N5−6.-P. 341−61.
- Cullen D.J., Hawkey C.J., Greenwood D.C. Peptic ulcer bleeding in the elderly: relative roles of Helicobacter pylori and non-steroidal antiinflammatory drugs. // Gut. 1997. — Vol. 41. — P. 459−62.
- Dajani E.Z., Callison D.A., Bianch R.G., Driskill D.R. Gastric antisecretory effects of E prostaglandins in rhesus monkeys. // Am. J. Dig. Dis. 1976. — Vol. 21. — P. 1020−8.
- Daly A.K. Pharmacogenetics of the major polymorphic metabolizing enzymes. // Fundam Clin Pharmacol. 2003. — Vol. 17, N 1. — P. 27−41.
- Davenport H. Destruction of the gastric mucosal barrier by detergents and urea. // Gastroenterology. -1968. Vol. 54. — P. 175−181.
- Davenport H. Effect of lisolecithin, digitonin and phospolipase upon the dog’s gastric mucosal barrier. // Gastroenterology. 1970. — Vol. 59. -P. 505−509
- De Morais S.M., Wilkinson G.R., Blaisdell J. et al. Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. // Mol. Pharmacol. 1994. Vol. 46, N 4. — P. 5948.
- De Morais S.M., Wilkinson GR, Blaisdell J. et al. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. // J. Biol. Chem. 1994. — Vol. 269, N 22. — P. 15 419−22.
- Dent J. An evidence-based appraisal of reflux disease management— the Genval Workshop Report. // Gut. 1999. — Vol. 44, Suppl. 2. — SI-SI6.
- Desta Z., Soukhova N.V., Flockhart D.A. Inhibition of cytochrome P450 isoforms by isoniazid: potent inhibition of CYP2C19 and CYP3A. // Antimicrob. Agents Chemother. 2001. — Vol. 45, N 2. — P. 382−92.
- Desta Z., Zhao X, Shin J.G. et al. Clinical significance of the cytochrome P450 2C19 genetic polymorphism // Clin. Pharmacokinet. -2002. Vol. 41, N 12. — P. 913−58.
- DeWitt D.L., Smith W.L. Primary structure of prostaglandin G/H synthase from sheep vesicular gland determined from the complementary DNA sequence // Proc. Natl. Acad. Sci. USA. 1988. — Vol. 85. — P. 14 121 416.
- Dimenas E., Carlsson G., Glise H. Relevance of norm values as part of the documentation of quality of life instruments for use in upper gastrointestinal disease. // Scand. J. Gastroenterol. 1996. — Vol. 221. — P. 8−13.
- Dupas J.L., Houcke P., Samoyeau R. Pantoprazole versus lansoprazole in French patients with reflux esophagitis // Gastroenterol. Clin. Biol. 2001. — Vol. 25, P. 245−250.
- Edwards S.J., Lind T, Lundell L. Systematic review of proton pump inhibitors for the acute treatment of reflux oesophagitis. // Aliment. Pharmacol. Ther. 2001. — Vol. 15, P. 1729−1736.
- Ehsanullah R.S., Page M.C., Tildesley G., Wood J.R. Prevention of gastroduodenal damage induced by non-steroidal anti-inflammatoiy drugs: controlled trial of ranitidine // BMJ. 1988. — Vol. 22 (297), N 6655. — P. 1017−21.
- El-Omar E., Penman J., Ardill J.E. Helicobacter pylori infection and abnormalities of acid secretion in patients with duodenal ulcer diseases. // Gastroenterology. 1995. — Vol. 109. — P. 681−691
- El-Serag HB, Sonnenberg A: Opposing time trends of peptic ulcer and reflux disease // Gut. 1998. — Vol. 43, P.327.
- Enck P., Dubois D., Marquis P. Quality of life in patients with upper gastrointestinal symptoms: results from the Domestic/International Gastroenterology Surveillance Study (DIGEST) // Scand. J. Gastroenterol. -1999.-Vol. 231. P.48−54.
- Euler A. R, Popiela T., Tytgat G.N. A multiclinic trial evaluating arbaprostil 15®-15-methyl prostaglandin E2. as a therapeutic agent for gastric ulcer. // Gastroenterology. 1989. — Vol. 96, N 4. — P. 967−71.
- Evans D.A., Krahn P., Narayanan N. The mephenytoin (cytochrome P450 2C 19) and dextromethorphan (cytochrome P450 2D6) polymorphisms in Saudi Arabians and Filipinos. // Pharmacogenetics. -1995.-Vol. 5, N2.-P. 64−71.
- Evans W.E. Pharmacogenomics: marshalling the human genome to individualise drug therapy// Gut. 2003. — Vol. 52, N Suppl n. — P. iilO-18.
- Evans W.E., Johnson J.A. Pharmacogenomics: the inherited basis for interindividual differences in drug response. // Annu. Rev. Genomics. Hum. Genet. 2001. — Vol. 2. P. 9−39.
- Fan X.G., Kelleher D., Fan X.J. Helicobacter pylori increases proliferation of gastric epithelial cells. // Gut. 1996. — Vol. 38. — P. 167— 73.
- Farrow D.C., Vaughan T.L., Hansten P.D. et al. Use of aspirin and other nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric cancer. // Cancer Epidemiol. Biomarkers Prev. 1998. — Vol. 7, N 2.-P. 97−102.
- FDA approves new indication and label changes for the arthritis drug, Vioxx. // FDA Talk Paper. — 11 il. — 2002.
- Feldman M., Burton M.E. Histamine 2-receptor antagonists. Standard therapy for acid-peptic diseases. 1. // N. Engl. J. Med. 1990. — Vol. 13(323), N24.-P. 1672−80.
- Feldman M., McMahon A.T. Do cyclooxygenase-2 inhibitors provide benefits similar to those of traditional nonsteroidal anti-inflammatory drugs, with less gastrointestinal toxicity? // Ann. Intern. Med. 2000. -Vol. 132, P. 134−43
- Feldman M., Colturi T.J. Effect of indomethacin on gastric acid and bicarbonate secretion in humans. // Gastroenterology. 1984. — Vol. 87, N 6.-P. 1339−43.
- Feldman M., Cryer B. Effects of age on gastric alkaline and non-parietal fluid secretion in humans. // Gerontology. 1998. — Vol. 44, N 4. -P. 222−27.
- Feldman M., McMahon A.T. Do cyclooxygenase-2 inhibitors provide benefits similar to those of traditional non-steroidal anti-inflammatory drugs with less gastrointestinal toxicity? // Ann. Intern. Med. 2000. — Vol. 132.-P. 1077
- Ferguson R.J., De Morais S.M., Benhamou S. et al. A new genetic defect in human CYP2C19: mutation of the initiation codon is responsible for poor metabolism of S-mephenytoin. // J. Pharmacol. Exp. Ther. 1998. -Vol. 284, N1.-P. 356−61.
- Fierz W. Challenge of personalized health care: to what extent is medicine already individualized and what are the future trends? // Med. Sci. Monit. 2004. — Vol. 10, N 5. — P. RA111−23.
- Fiorucci S., Antonelli E., Santucci L. Gastrointestinal Safety of Nitric Oxidederived aspirin is related to inhibition of ICE-like cysteine proteases in rats. // Gastroenterology. 1999. — Vol. 116. — P. 1089−1106
- Fitzgerald G.A., Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. // N. Engl. J. Med. 2001. — Vol. 345. — P. 433−42.
- Fletcher B.S., Kujubu D.A., Perrin D.M. et al. Structure of the mitogen-inducible TIS 10 gene and demonstration that the TIS 10-encoded protein is a functional prostaglandin G/H synthase. // J. boil.Chem. 1992. -Vol. 267.-P. 4338−4344.
- Fries J.F. Non-steroidal anti-inflammatory drug safety: a view from ARAMIS databank. // Curr. Opinion Rheumatol. 1996. — Vol. 8. — Suppl. l.-P. 3−7.
- Fuhr U., Jetter A. Rabeprazole: pharmacokinetics and pharmacokinetic drug interactions // Pharmazie. 2002. — Vol. 57, N 9. — P. 595−601.
- Furuta T., Ohashi K., Kamata T. et al. Effect of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer // Ann. Intern. Med. 1998. — Vol. 15 (129), N 12. — P. 102 730.
- Furuta T., Shirai N., Sugimoto M., Ohashi K., Ishizaki T. Pharmacogenomics of proton pump inhibitors. // Pharmacogenomics. -2004.-Vol. 5, N2.-P. 181−202.
- Furuta T., Shirai N, Sugimoto M. Controversy in polymorphisms of interleukin-lbeta in gastric cancer risks. // J. Gastroenterol. 2004. — Vol. 39, N5.-P. 501−3.
- Furuta T., Shirai N. Takashima M. et al. Effects of genotypic differences in CYP2C19 status on cure rates for Helicobacter pylori infection by dual therapy with rabeprazole plus amoxicillin // Pharmacogenetics. 2001. — Vol. 11, N 4. — P. 341−8.
- Furuta T., Shirai N., Xiao F. et al. Polymorphism of interleukin-lbeta affects the eradication rates of Helicobacter pylori by triple therapy // Clin. Gastroenterol. Hepatol. 2004. — Vol. 2, N 1. — P. 22−30.
- Furuta T., Baba S., Takashima M. Effect of Helicobacter pylori infection on gastric juice pH. // Scand. J. Gastroenterol. 1998. — Vol. 33, N4.-P. 357−63.
- Gaikovitch E.A., Cascorbi I., Mrozikiewicz P.M. et al. Polymorphisms of drug-metabolizing enzymes CYP2C9, CYP2C19, CYP2D6, CYP1A1, NAT2 and of P-glycoprotein in a Russian population. // Eur. J. Clin. Pharmacol. 2003. — Vol. 59, N 4. — P. 303−12.
- Garcia Rodriguez L.A. Non-steroidal anti-inflammatory drugs, ulcers and risk: a collaborative meta-analysis // Semin. Arthritis Rheum. 1997. -Vol. 26. — P. 16−20.
- Glise H., Wiklund I. Health-related quality of life and gastrointestinal disease. // J. Gastroenterol. Hepatol. 2002. — Vol. 17, Suppl. 1. — P. 72−84.
- Goldstein J.A., de Morais S.M. Biochemistry and molecular biology of the human CYP2C subfamily // Pharmacogenetics. 1994. — Vol. 4, N 6. -P. 285−99.
- Goldstein J.A., Faletto M.B., Romkes-Sparks M. et al. Evidence that CYP2C19 is the major (S)-mephenytoin 4-hydroxylase in humans// Biochemistry. 1994. — Vol. 22(33), N 7. — P. 1743−52.
- Gonzalez H.M., Romero E.M., Peregrina A.A. et al. CYP2C19- and CYP3A4-dependent omeprazole metabolism in West Mexicans // J. Clin. Pharmacol. 2003. — Vol. 43, N 11. — P. 1211−5.
- Graham D. Helicobacter pylori, Blackwell, 2002,220 p.
- Graham D.Y., Lacey S.J., Dobbs S.M. Gastric adaptation occurs with aspirin administration in man. // Dig. Dis. Sci. 1983. — Vol. 28. — P. 1−6.
- Graham D.Y., Opekun A., Lew G.M. Ablation of exaggerated meal-stimulated gastrin release in duodenal ulcer patients after clearance of Helicobacter (Campylobacter) pylori infection. // Am. J. Gastroenterol. -1990.-Vol. 85, N4.-P. 394−8.
- Graham D.Y., Smith J.L., Spjut H.J. et al. Gastric adaptation. Studies in humans during continuous aspirin administration. // Gastroenterology. -1988.-Vol. 95.-P. 327−33.
- Griese E.U., Ilett K.F., Kitteringham N.R. et al. Allele and genotype frequencies of polymorphic cytochromes P4502D6, 2C19 and 2E1 in aborigines from western Australia// Pharmacogenetics. 2001. — Vol. 11, Nl.-P. 69−76.
- Grossi E., Borghi C., Cerchiari E.L. Analogue chromatic continuous scale (ACCS): a new method for pain assessment // Clin. Exp. Rheumatol. 1983. — Vol. 1, N 4. — P. 337−40.
- Guo M., Hay B.A. Cell proliferation and apoptosis. // Current Opinion in Cell Biology. 1999. — Vol. 11.- P.745−752.
- Hall P.A., Levison D.A. Assessment of cell proliferation in histological material // J. Clin. Pathol. -1990. Vol. 43. — P. 184.
- Hamlet A., Lindholm C., Nilsson O. Aspirin-induced gastritis, like Helicobacter pylori-induced gastritis disinhibits acid secretion in humans: relation to cytokine expression // Scand. J. Gastroenterol. 1998. — Vol. 33, N4.-P. 346−356.
- Hauser W., Grandt D. Measuring quality of life in gastroenterology -concepts, instruments and problems // Z. Gastroenterol. 2001. — Vol. 39, N6.-P. 475−81.
- Hawkey C.J. COX-2 inhibitors. // Lancet. 1999. — Vol. 353. — P. 307−314.
- Hawkey C.J. Future treatment for arthritis: new NSAIDs, NONSAIDs, or no NSAIDs? // Gastroenterology. 1995. — Vol. 109, N 2. — P. 614−616.
- Hawkey C.J. The gastroenterologist’s caseload: contribution of the rheumatologist // Semin. Arthritis Rheum. 1997. — Vol. 26, N 6. — P. 1115.
- Hawkey C.J., Cullen D.J.E. Ibuprofen versus other non-steroidal antiinflammatory drugs: use in general practice and patient perception // Aliment. Pharmacol. Ther. 2000. — Vol. 14. — P. 187−91.
- Hawkey C.J. Non-steroidal anti-inflammatory drug gastropathy: causes and treatment. // Scand. J. Gastroenterol. 1996. — Vol. 31, Suppl. 220.-P. 124−127.
- He N., Yan F.X., Huang S.L. et al. CYP2C19 genotype and S-mephenytoin 4-hydroxylation phenotype in a Chinese Dai population // Clin. Pharmacol. 2002. — Vol. 58, N 1. — P. 15−8.
- Helander H.F. The normal gastric mucosa. In: Stomach ed. by S. Gustavsson, Churchill Livingston, London. 1992. — P. 1−20.
- Helicobacter pylori. Basic mechanisms to clinical cure 2002 ed. by Hunt R.H. and Tytgat G. 2003. — Kluwer Academic Publishers and Axcan Pharma. — 538 p.
- Heresbach D., Raoul J.L., Bretagne J.F. Helicobacter pylori: a risk and severity factor of non-steroidal anti-inflammatory drug induced gastropathy // Gut. 1992. — Vol. 33, N 12. — P. 1608−11.
- Herrlin K., Massele A.Y., Jande M. et al. Tanzanians have a decreased capacity to metabolize omeprazole and mephenytoin in relation to their CYP2C19 genotype // Clin. Pharmacol. Ther. 1998. — Vol. 64, N 4. — P. 391−401.
- Hirose M., Miwa H., Kobayashi O. Inhibition of proliferation of gastric epithelial cells by a cyclooxygenase 2 inhibitor, JTE522, is also mediated by a PGE2- independent pathway // Aliment. Pharmacol. Ther. -2002.-Vol. 16.-P. 83−89.
- Ho S., Hoyle J.A., Lewis F.A. Direct polymerase chain reaction for detection of Helicobacter pylori in humans and animals // J. Clin. Microbiol. 1991. — Vol. 29. — P. 2543−49.
- Hokari K., Sugiyama T., Kato M. et al. Efficacy of triple therapy with rabeprazole for Helicobacter pylori infection and CYP2C19 genetic polymorphism. // Aliment. Pharmacol. Ther. 2001. — Vol. 15, N 9. — P. 1479−84.
- Hollander D. Gastrointestinal complications of non-steroidal antiinflammatory drugs: Prophylactic and therapeutic strategies. // Am. J. Med. 1994. — Vol. 96. — P. 274−281.
- Horai Y., Kimura M., Furuie H. et al. Pharmacodynamic effects and kinetic disposition of rabeprazole in relation to CYP2C19 genotypes // Aliment. Pharmacol. Ther. 2001. — Vol. 15, N 6. — P. 793−803.
- Hoskins J.M., Shenfield G.M., Gross A.S. Relationship between proguanil metabolic ratio and CYP2C19 genotype in a Caucasian population // Br. J. Clin. Pharmacol. 1998. — Vol. 46, N 5. — P. 499−504.
- Howden C.W., Ballard E.D., Robieson W. Evidence for therapeutic equivalence of lansoprazole 30 mg and esomeprazole 40 mg in the treatment of erosive oesophagitis // Clin. Drug. Invest. 2002. — Vol. 22. -P. 99−109.
- Hudson N., Balsitis M., Filipowicz F., Hawkey C.J. Effect of Helicobacter pylori colonisation on gastric mucosal eicosanoid synthesis in patients taking nonsteroidal anti-inflammatory drugs // Gut. 1993. — Vol. 34, N6.-P. 748−51.
- Hull M.A., Thomson J.L., Hawkey C.J. Expression of cyclooxygenase 1 and 2 by human gastric endothelial cells // Gut. 1999. — Vol. 45. — P. 529−536.
- Hurley J.W., Crandall L.A.Jr. The effect of the salicylates upon the stomachs of the dogs // Gastroenterology. 1964. — Vol. 46. — P. 36−43.
- Ibeanu G.C., Goldstein J.A., Meyer U. et al. Identification of new human CYP2C19 alleles (CYP2C19*6 and CYP2C19*2B) in a Caucasian poor metabolizer of mephenytoin// J. Pharmacol. Exp. Ther. 1998. -Vol. 286, N3.-P. 1490−5.
- Inamori M., Togawa J., Takahashi K. et al. Comparison of the effect on intragastric pH of a single dose of omeprazole or rabeprazole: which is suitable for on-demand therapy? // J. Gastroenterol. Hepatol. 2003. -Vol. 18, N9.-P. 1034−8.
- Ingelman-Sundberg M. Implications of polymorphic cytochrome P450-dependent drugs metabolism for drug development // Drug metabolism and disposition. 2000. — Vol. 29, N 4, Part 2.
- Ingelman-Sundberg M. Pharmacogenetics: an opportunity for a safer and more efficient pharmacotherapy // J. Intern. Med. 2001. — Vol. 250, N3.-P. 186−200.
- Ishizaki T., Horai Y. Review article: cytochrome P450 and the metabolism of proton pump inhibitors emphasis on rabeprazole // Aliment. Pharmacol. Ther. — 1999. — Vol. 13. — P. 27−36.
- Ishizaki T., Sohn D.R., Kobayashi K. et al. Interethnic differences in omeprazole metabolism in the two S-mephenytoin hydroxylation phenotypes studied in Caucasians and Orientals. // Ther. Drug. Monit. -1994.-Vol. 16, N2.-P. 214−5.
- Jain K.K. Personalized medicine // Curr. Opin. Mol. Ther. 2002. -Vol. 4, N6.-P. 548−58.
- Janssen M., Baak L.C., Jansen J.B. Effects of indomethacin on intragastric pH and meal-stimulated serum gastrin secretion in rheumatoid arthritis patients // Aliment. Pharmacol. Ther. 1993. — Vol. 7, N 4. — P. 393−400.
- Jasunaga J., Shinomura J., Kanayama S. Improved fold width and increased acid secretrion after eradication of the organism in Helicobacterpylori associated enlarged fold gastritis // Gut. 1994. — Vol. 35. — P. 1571−1574.
- Jensen D.M. Management of severe ulcer rebleeding // N. Engl. J. Med. 1999. — Vol. 340, N 10. — P. 799−801.
- Jones N.L., Shannon P. Т., Cutz E. Increase in proliferation and apoptosis of gastric epithelial cells early in the natural history of Helicobacter pylori infection // Am. J. Pathol. 1997. — Vol. 151. — P. 1695 — 1703.
- Jones R.H., Lydeard S., Dunleavey J. Problems with implementing guidelines: a randomised controlled trial of consensus management of dyspepsia // Qual. Health Care. 1993. — Vol. 2, N 4. — P. 217−21.
- Jones R.H., Tait C.L. Gastrointestinal side-effects of NSAIDs in the community. // Br. J. Clin. Pract. 1995. — Vol. 49, N 2. — P. 67−70.
- Jurima-Romet M., Goldstein J.A., LeBelle M., Aubin R.A., Foster B.C., Walop W., Rode A. CYP2C19 genotyping and associated mephenytoin hydroxylation polymorphism in a Canadian Inuit population // Pharmacogenetics. 1996. — Vol. 6, N 4. — P. 329−39.
- Kahrilas P.J. Strategies for medical management of reflux disease. // Baillieres Best Pract. Res. Clin. Gastroenterol. 2000. — Vol. 14. — P. 775 791.
- Kakiuchi Y., Kawano S., Tsuji M. Helicobacter pylori and NSAIDs enhance COX-2 expression in gastric epithelial cells // Gut. 1999. — Vol. 45.-A94.
- Kalow W. The genetic defect of mephenytoin hydroxylation. // Xenobiotica. 1986. — Vol. 16, N 5. — P. 379−89.
- Kaneko A., Bergqvist Y., Taleo G., Kobayakawa Т., Ishizaki Т., Bjorkman A. Proguanil disposition and toxicity in malaria patients from Vanuatu with high frequencies of CYP2C19 mutations. // Pharmacogenetics. 1999. — Vol. 9(3). — P. 317−26.
- Kaneko A., Lum J.K., Yaviong L. et al. High and variable frequencies of CYP2C19 mutations: medical consequences of poor drug metabolism in Vanuatu and other Pacific islands. // Pharmacogenetics. 1999. — Vol. 9, N5.-P. 581−90.
- Kargman S. et al. Characterization of prostaglandin G/H synthase-1 and -2 in rat, dog, monkey, and human gastrointestinal tracts // Gastroenterology. 1996. — Vol. 111. — P. 445−454.
- Karnes W.E.Jr., Ohning G.V., Sytnik B. Elevation of meal-stimulated gastrin release in subjects with Helicobacter pylori infection: reversal by low intragastric pH. // Rev. Infect. Dis. 1991. — Vol. 13, Suppl 8. — P. S665−670.
- Katsuki H., Nakamura C., Arimori K., Fujiyama S., Nakano M. Genetic polymorphism of CYP2C19 and lansoprazole pharmacokinetics in Japanese subjects // Eur. J. Clin. Pharmacol. 1997. — Vol. 52, N 5. — P. 391−6.
- Kearns G.L., Winter H.S. Proton pump inhibitors in pediatrics: relevant pharmacokinetics and pharmacodynamics // J. Pediatr. Gastroenterol. Nutr. 2003. — Vol. 37, Suppl. 1. — P. S52−9.
- Kelly S.M., Jenner J.R., Dickinson R.J., Hunter J.O. Increased gastric juice epidermal growth factor after non-steroidal anti-inflammatory drug ingestion // Gut. 1994. — Vol. 35, N 5. — P.611−614.
- Kerr J.R.F., Wyllie A.H., Currie A.R. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics // Br. J. Cancer. 1972. — Vol. 26. — P. 239−257.
- Khoda K., Tanaka K., Aiba Y. Role of apoptosis induced by Helicobacter pylori infection in the development of duodenal ulcer // Gut. 1999. — Vol. 44. — P. 456−462.
- Kim J.G., Graham D.Y. The Misoprostol Study Group: Helicobacter pylori infection and the development of gastric or duodenal ulcer in arthritic patients receiving chronic NSAID therapy // Am. J. Gastroenterol. -1994.-Vol. 89.-P. 203.
- Kim K.A., Shon J.H., Park J.Y. et al. Enantioselective disposition of lansoprazole in extensive and poor metabolizers of CYP2C19 // Clin. Pharmacol. Ther. 2002. — Vol. 72, N 1. — P. 90−9.
- Kim T.I., Lee Y.C., Lee K.H. Effects of non-steroidal antiinflammatory drugs on Helicobacter pylori-infected gastric mucosae of mice: apoptosis, cell proliferation, and inflammatory activity // Infect. Immun. 2001. — Vol. 69, N 8. — P. 5056−5063.
- Kimura M., Ieiri I., Mamiya K., Urae A., Higuchi S. Genetic polymorphism of cytochrome P450s, CYP2C19, and CYP2C9 in a Japanese population // Ther. Drug. Monit. 1998. — Vol. 20, N 3. — P. 2437.
- Kinoshita K., Taupin D.R., Itoh H. Distinct pathways of cell migration and antiapoptotic response to epithelial injury: structure-function analysis of human intestinal trefoil factor // Mol. Cell. Biol. 2000. — Vol. 20, N 13.-P. 4680−4690.
- Klinkenberg-Knol E.C., Nelis F., Dent J. et al. Long-term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety, and influence on gastric mucosa // Gastroenterology. 2000. — Vol. 118. — P. 661−669.
- Klotz U. Pharmacokinetic considerations in the eradication of Helicobacter pylori // Clin. Pharmacokinet. 2000. — Vol. 38. — P. 243−70.
- Ko J. W., Sukhova N., Thacker D., Chen P., Flockhart D.A. Evaluation of omeprazole and lansoprazole as inhibitors of cytochrome P450 isoforms. // Drug Metab. Dispos. 1997. — Vol. 25, N 7. — P. 853−62.
- Konturek J.W., Dembinski A., Konturek S.J. Infection of Helicobacter pylori in gastric adaptation to continued administration of aspirin in humans // Gastroenterology. 1998. — Vol. 114. — P. 245−255.
- Konturek P.C. Physiological, immunohistochemical and molecular aspects of gastric adaptation to stress, aspirin and to H. pylori-derived gastrotoxins // J. Physiol. Pharmacol. 1997. — Vol. 48, N 1. — P. 3−42.
- Konturek P.C., Brzozowski T., Konturek S.J. Bacterial Iipopolysaccharide protects gastric mucosa against acute injury in rats by activation of genes for cyclooxygenases and endogenous prostaglandins // Digestion. 1998. — Vol. 59, N 4. — P. 284−297.
- Konturek S.J., Tasler J., Bilski J., Kania J. Prostaglandins and alkaline secretion from oxyntic, antral, and duodenal mucosa of the dog // Am. J. Physiol. 1983. — Vol. 245, N 4. — P. 539−46.
- Koyama E., Tanaka T., Chiba K. et al. Steady-state plasma concentrations of imipramine and desipramine in relation to S-mephenytoin 4-hydroxylation status in Japanese depressive patients// J. Clin. Psychopharmacol. 1996. — Vol. 16, N 4. — P. 286−93.
- Kubota T., Chiba K., Ishizaki T. Genotyping of S-mephenytoin 4-hydroxylation in an extended Japanese population. // Clin. Pharmacol. Ther. 1996. — Vol. 60, N 6. — P. 661−6.
- Kulkarni S.G., Parikh S.S., Shankhpal P.D. Gastric emptying of solids in longterm NSAID users: correlation with endoscopic findings and Helicobacter pylori status // Am. J. Gastroenterol. 1999. — Vol. 94, N 2. -P. 382−386.
- Kurata J.H., Nogawa A.N., Noritake D. NSAIDs increase risk of gastrointestinal bleeding in primary care patients with dyspepsia. // J. Fam. Pract. 1997. — Vol. 45, N 3. — P. 227−35.
- Kurinets A., Lichtenberger L.M. Phosphatidylcholine-associated aspirin accelerates healing of gastric ulcers in rats. // Dig. Dis. Sci. 1998. -Vol. 43, N4.-P. 786−90.
- Kurumbail R.J., Stevens A.M., Gierse J.K. Structural basis for selective inhibition of cyclooxygenase-2 by anti-inflammatory agents. // Nature. 1996. — Vol. 384, N 19/26. — P. 644−648.
- Kuwayama H., Eastwood G.L. Effects of water immersion restraint stress and chronic indomethacin ingestion on gastric antral and fundic epithelial proliferation // Gastroenterology. 1985. — Vol. 88, N 1, Pt 2. -P. 362−5.
- Kwo P.Y., Tremaine W.J. Non-steroidal anti-inflammatory drug-induced enteropathy: case discussion and review of the literature. // Mayo Clin. Proc. 1995. — Vol. 70, N 1. — P. 55−61.
- Labeling changes for arthritis drug Celebrex. // FDA Talk Paper. N7.-2002.
- Labenz J., Peitz U., Kohl H. Helicobacter pylori increases the risk of peptic ulcer bleeding: a case-control study // Ital. J. Gastroenterol. Hepatol. -1999.-Vol.31.-P. 110−15.
- Lachman L., Howden C.W. Twenty-four-hour intragastric pH: tolerance within 5 days of continuous ranitidine administration. // Am. J. Gastroenterol. 2000. — Vol. 95. — P. 57−61.
- Laine L., Cominelli F., Sloane R. Interaction of NSAIDs and Helicobacter pylori on gastrointestinal injury and prostaglandin production: a controlled double-blind trial // Aliment. Pharmacol. Ther. -1995.-Vol. 9, N2.-P. 127−35.
- Laine L., Wogen J., Yu H. Gastrointestinal health care resource utilization with chronic use of COX-2-specific inhibitors versus traditional NSAIDs // Gastroenterology. 2003. — Vol. 125, N 2. — P. 389−95.
- Laine L. The role of proton pump inhibitors in NSAID-associated gastropathy and upper gastrointestinal symptoms // Rev. Gastroenterol. Disord. 2003. — Vol. 3, Suppl. 4. — S.30−9.
- Lamba J.K., Dhiman R.K., Kohli K.K. Genetic polymorphism of the hepatic cytochrome P450 2C19 in north Indian subjects. // Clin. Pharmacol. Ther. 1998. — Vol. 63, N 4. — P. 422−7.
- Lanas A. Nonsteroidal anti-inflammatory drugs, low-dose aspirin, and potential ways of reducing the risk of complications. // Eur. J. Gastroenterol. Hepatol. 2000. — Vol. 13. — P. 623−6.
- Langenbach R., Morham S.G., Tiano H.F. et al. Prostaglandin synthase 1 gene disruption in mice reduces arachidonic acid-inducedinflammation and indomethacin-induced gastric ulceration // Cell. 1995. -Vol. 83.-P. 483−492.
- Langman M.J., Weil J., Wainwright P. Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs // Lancet. 1994. — Vol. 343, N 8905. — P. 1075−8.
- Langman M.J., Cheng K.K., Gilman E.A. Effect of anti-inflammatory drugs on overall risk of common cancer: case-control study in general practice research database // BMJ. 2000. — Vol. 320, N 7250. — P. 164 246.
- Lanza F.L. A review of gastric ulcer and gastroduodenal injury in normal volunteers receiving aspirin and other non-steroidal antiinflammatory drugs // Scand. J. Gastroenterol. 1989. — Vol. 163. — P. 2431.
- Larkai E.N., Smith J.L., Lidsky M.D. Gastroduodenal mucosa and dyspeptic symptoms in arthritic patients during chronic non-steroidal antiinflammatory drug use // Am. J. Gastroenterol. 1987. — Vol. 82, N 11. -P. 1153−8.
- Lauener R.P. Allergien: Genetisch determiniertes Schicksal Oder durch Umwelteinflusse bestimmte Krankheit? Die Ontogenese der ImmunKompetenz und Allergie-Entstehung. Monatsschrft Kinderheilkunde. -2003. Suppl. 1.
- Lazzaroni M., Bianchi Porro G. Non-steroidal anti-inflammatory drug gastropathy: clinical results with H2 antagonists and proton pump inhibitors // Ital. J. Gastroenterol. Hepatol. 1999. — Vol. 31, Suppl. 1. — P. S73−8.
- Lee M., Feldman M. The aging stomach: implications for NSAID Gastropathy // Gut. 1999. — Vol. 41. — P. 425−426.
- Leers M.P., Kolgen W., Bjorklund V. et al. Immunocytochemical detection and mapping of a cytokeratin-18 neoepitope exposed during early apoptosis // J. Pathol. 1999. — Vol. 187. — P. 567.
- Levi S., Goodlad R.A., Lee C.Y. Inhibitory effect of non-steroidal anti-inflammatory drugs on mucosal cell proliferation associated with gastric ulcer healing // Lancet. 1990. — Vol. 336, N 8719. — P. 840−3.
- Levine R.A., Schwartzel E.H. Effect of indomethacin on basal and histamine stimulated human gastric acid secretion. // Gut. 1984. — Vol. 25, N7.-P. 718−722
- Levy A., Banwait K.S., DiMarino A. et al. Utility of twenty-four esophageal pH monitoring in patients with persistent symptoms on PPI therapy. // Gastroenterology. 2004. — Vol. 4, Suppl. 2. — A19.
- Li E.K., Sung J.J., Suen R. Helicobacter pylori infection increases the risk of peptic ulcers in chronic users of non-steroidal anti-inflammatory drugs // Scand. J. Rheumatol. 1996. — Vol. 25, N 1. — P. 42−46.
- Lichtenberger L.M., Ulloa C., Romero J.J. Non-steroidal antiinflammatory drug and phospholipid prodrugs: combination therapy with antisecretory agents in rats // Gastroenterology. 1996. — Vol. 111. — P. 990−995.
- Lin J.H., Lu A.Y.H. Role of Pharmacokinetics and Metabolism in Drug Discovery and Development// Pharmacological reviews. 1997. -Vol. 49, N4.-P. 403−449.
- Lipkin M. Gastric cell regeneration. // Arch. Fr. Mai. ApP. Dig. -1972. Vol. 61, N 11. — P. 691−3.
- Lipkin M. Proliferation and differentiation of gastrointestinal cells. // Physiol Rev. 1973. — Vol. 53, N 4. — P. 891−915.
- Lipscomb G.R., Campbell F., Rees W.D. The influence of age, gender, Helicobacter pylori and smoking on gastric mucosal adaptation tonon-steroidal anti-inflammatory drugs // Aliment. Pharmacol. Ther. -1997. Vol. 11, N 5. — P. 907−912.
- Lipsky P.E., Brooks P. Unresolved issues in the role of cyclooxygenase-2 in normal physiologic processes disease // Arch. Intern. Med. 2000. — Vol. 160. — P. 913−920.
- Loeb D.S., Talley N.J., Ahlquist D.A. Long-term non-steroidal antiinflammatory drug use and gastroduodenal injury: the role of Helicobacter pylori. // Gastroenterology. 1992. — Vol. 102, N 6. — P. 1899−905.
- Lu Y.H. Drug-metabolism research challenges in the new millenium // Drug metabolism metabolism and disposition. 2002. — Vol. 26, N 12.
- Lundell L., Miettinen P., Myrvold H.E. et al. Continued (5-year) followup of a randomized clinical study comparing antireflux surgery and omeprazole in gastroesophageal reflux disease // J. Am. Coll. Surg. 2001. -Vol. 192.-P. 172−179.
- Lynch D.A.F., Mapstone N.P., Lewis F. Correlation between cell proliferation in Helicobacter pylori associated gastritis and histological scoring using the Sidney system // Gut. 1993. — Vol. 34. — P. 197.
- Malfertheiner P., Labenz J. Does Helicobacter pylori status affect nonsteroidal anti-inflammatory drug-associated gastroduodenal pathology? // Am. J. Med. 1998. — Vol. 104, N 3A. — P. 35S-40S.
- Malfertheiner P., Megraud F., CMorain C. Current concepts in the management of Helicobacter pylori infection the Maastricht II — 2000 Consensus Report // Aliment. Pharmacol. Ther. — 2002. — Vol. 16, N 2. -P. 167−80.
- Mamdani M., Juurlink D.N., Kopp A., Naglie G., Austin P.C., Laupacis A. Gastrointestinal bleeding after the introduction of COX 2 inhibitors: ecological study // BMJ. 2004. — Vol. 328, N 7453. — P. 14 156.
- Mamiya K., Hadama A., Yukawa E., Ieiri I., Otsubo K., Ninomiya H., Tashiro N., Higuchi S. CYP2C19 polymorphism effect on phenobarbitone.
- Pharmacokinetics in Japanese patients with epilepsy: analysis by population pharmacokinetics. // Eur. J. Clin. Pharmacol. 2000. — Vol. 55, N11−12.-P. 821−5.
- Manning F.C.R., Patierno S.R. Apoptosis: inhibitor or instigator of carcinogenesis? // Cancer Invest. 1996. — Vol. 14. — P. 455−465.
- Marandi T., Dahl M.L., Kiivet R.A., Rago L., Sjoqvist F. Debrisoquin and S-mephenytoin hydroxylation phenotypes and CYP2D6 genotypes in an Estonian population// Pharmacol. Toxicol. 1996. — Vol. 78, N 5. — P. 303−7.
- Marandi T., Dahl M.L., Rago L., Kiivet R., Sjoqvist F. Debrisoquine and S-mephenytoin hydroxylation polymorphisms in a Russian population living in Estonia// Eur. J. Clin. Pharmacol. 1997. — Vol. 53, N 3−4. — P. 257−60.
- Marinac J.S., Balian J.D., Foxworth J.W. et al. Determination of CYP2C19 phenotype in black Americans with omeprazole: correlation with genotype. // Clin. Pharmacol. Ther. 1996. — Vol. 60, N 2. — P. 13 844.
- Marnett L.J., Kalgutkar A.S. Cyclooxygenase-2 inhibitors: discovery, selectivity and the future // TiPS. 1999. — Vol. 20. — P. 465−469.
- Marshall B. Pioneers of Helicobacter pylori-nfection, 2002, 324 p.
- Masferrer J.L., Koki A., Seibert K. COX-2 inhibitors. A new class of antiangiogenic agents // Ann. N.Y. Acad. Sci. 1999. — Vol. 889. — P. 8486.
- Masferrer J.L., Seibert K., Zweifel B. & Needleman P. Endogenous glucocorticoids regulate an inducible cyclooxygenase enzyme // Proc. Natl. Acad. Sci. USA. 1992. — Vol. 89. — P. 3917−3921.
- McCarthy D. Non-steroidal anti-inflammatory drug-related gastrointestinal toxicity: definitions and epidemiology // Am. J. Med. -1998.-Vol. 105.-P. 3−9.
- McCormack J.R., Rangno R. Digging for data from the COX-2 trials. // Can. Med. Assoc. J. 2002. — Vol. 166. — P. 1649−50.
- McCormick D., Chong H.M., Hobbs C. Detection of the Ki-67 antigen in fixed and wax-embedded sections with monoclonal antibody MIB-1 // Histopathology. 1993. — Vol. 22. — P. 355−360.
- McGowan C.C., Cover T.Z., Blaser M.J. Helicobacter pylori and gastric acid: biological and therapeutic implications // Gastroenterology.1996.-Vol. 110, N3.-P. 926−938
- McGrath J., Sy R., Gregor J. Gastrointestinal toxicity and tolerability of COX-2 selective inhibitors: a meta-analysis // Gastroenterology. 2004. -Vol. 4, Suppl. 2. — A616.
- Meibohm B., Beierle I., Derendorf H. How important are gender differences in pharmacokinetics? // Clin. Pharmacokinet. 2002. — Vol. 41, N5.-P. 329−42.
- Meloxicam a safer NSAID? // Drug Ther. Bull. — 1998. — Vol. 36. -P. 62−4.
- Meyer U.A., Zanger U.M. Molecular mechanisms of genetic polymorphisms of drug metabolism. // Annu. Rev. Pharmacol. Toxicol.1997.-Vol. 37.-P. 269−96.
- Micklewright R., Lane S., Linley W. et al. NSAIDs, gastroprotection and cyclo-oxygenase-2-selective inhibitors // Aliment. Pharmacol. Ther.2003.-Vol. 17.-P. 321−332.
- Mizuno H., Sakamoto C., Matsuda K. et al. Induction of cyclooxygenase 2 in gastric mucosal lesions and its inhibition by the specific antagonist delays healing in mice. // Gastroenterology. 1997. -Vol. 112.-P. 387−97.
- Moayedi P., Soo S., Deeks J. Systematic review and economic evaluation of Helicobacter pylori eradication treatment for non-ulcer dyspepsia. // BMJ. 2000. — Vol. 321. — P. 659−64.
- Mochiki E., Nakabayashi T., Suzuki H. PGE2 stimulates motilin release via a cholinergic muscarinic pathway in the dog. // Neurogastroenterol. Mot. 2000. — Vol. 12. — P. 523−530.
- Modlin I., Sachs G. Acid-related diseases, 2000, 870 p.
- Modlin I.M., Kidd M., Lye K.D. Historical perspectives on the treatment of gastroesophageal reflux disease. // Gastrointest. Endosc. Clin. N. Am. 2003. — Vol. 13, N 1. — P. 19−55, vii-viii.
- Mohammed S., Croom-H D.W. Gastropathy due to celecoxib, a cyclooxygenase-2 inhibitor // NEJM. 1999. — Vol. 340. — P. 2005−2006.
- Moncada S., Higgs A. The L-arginin-nitric oxide pathway. // NEJM. -1993. Vol. 27. — P. 2002−2012.
- Moss S.F. Cellular markers in the gastric precancerous process. // Aliment. Pharmacol. Ther. 1998. — Vol. 12, Suppl. 1. — P. 91−109.
- Moss S.F., Calam J., Agarwal B. Helicobacter pylori infection induced gastric epithelial apoptosis in vivo. // Gastroenterology. — 1995. -Vol. 108.-P. 171.
- Moss S.F. Helicobacter pylori and apoptosis. // Yale J. Biol. Med. -1998.-Vol. 71, N2.- P. 53−61.
- Moss S.F. The carcinogenic effect of H. pylori on the gastric epithelial cell. // J. Physiol. Pharmacol. 1999. — Vol. 50, N 5. — P. 847−56.
- Murphy M.S. Growth factors and the gastrointestinal tract. // Nutrition. 1998. — Vol. 14, N 10. — P. 771−74.
- Nelson D.R., Koymans L., Kamataki T. et al. P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. // Pharmacogenetics. 1996. — Vol. 6, N 1. — P. 1−42.
- Niemcryk S., Joshua-Gotlib S., Levine D. The outpatient experience of GERD patients in US: An analysis of the 1998−2000 National ambulatory medical care // Gastroenterology. 2004. — Vol. 126, N4, Suppl. 2.-P. S1213.
- Nishiyama R., Sakaguchi T., Kinugasa T. Interleukin-2 receptor beta subunitdependent and -independent regulation of intestinal epithelial tight junctions. // J. Biol. Chem. 2001. — Vol. 276, N 38. — P.35 571−80.
- Nowak M.P., Sellers E.M., Tyndale R.F. Canadian Native Indians exhibit unique CYP2A6 and CYP2C19 mutant allele frequencies // Clin. Pharmacol. Ther. 1998. — Vol. 64, N 4. — P. 378−83.
- Ohyama S., Yonemura Y., Miwa K. Proliferation assay of human gastric remnant by bromodeoxyuridine and flow cytometry. // Gastroenterology. 1992. — Vol. 103. — P. 789−93.
- Penney A.G., Malcontenti-Wilson C., O’Brien P.E. NSAID-induced delay in gastric ulcer healing is not associated with decreased epithelial cell proliferation in rats // Dig. Dis. Sci. 1995. — Vol. 40, N 12. — P. 2684−93.
- Perri F., Qasim A., Marras L., O’Morain C. Treatment of Helicobacter pylori infection. // Helicobacter. 2003. — Vol. 8, Suppl. 1. — P. 53−60.
- Pirmohamed M., James S., Meakin S. et al. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. // BMJ. 2004. — Vol. 329, N 7456. — P. 15−19.
- Podolsky D.K. Review article: healing after inflammatory injury -coordination of a regulatory peptide network // Aliment. Pharmacol. Ther. 2000. — Vol. 14, Suppl. 1. — P. 87−93.
- Pollock B.G., Perel J.M., Kirshner M., Altieri L.P., Yeager A.L., Reynolds C.F.3rd. S-mephenytoin 4-hydroxylation in older Americans. // Eur. J. Clin. Pharmacol. 1991. — Vol. 40, N 6. — P. 609−11.
- Potten C., Booth C., Pritchard D.M. The intestinal epithelial stem cell: the mucosal governor. // Int. J. ExP. Path. 1997. — Vol. 78. — P. 219−243.
- Potten C.S. Stem cells in gastrointestinal epithelium: numbers, characteristics and death. // Philos. Trans. R. Soc. Lond. B. Biol. Sci. -1998. Vol. 353, N 1370. — P. 821−30.
- Poulsom R., Begos D.E., Modlin I.M. Molecular aspects of restitution: functions of trefoil peptides // Yale J. Biol. Med. 1996. — Vol. 69, N 2. -P. 137−46.
- Prescott S.M., White R.L. Self-promotion? Intimate connections between APC and prostaglandin H synthase-2. // Cell. 1996. — Vol. 87. -P. 783−786.
- Quigley E.M. New developments in the pathophysiology of gastroesophageal reflux disease (GERD): implications for patient management. // Aliment. Pharmacol. Ther. 2003. — Vol. 17, Suppl 2. — P. 43−51.
- Rademaker J.W., Rainsford K.D., Stetsko P.I. The effect of indomethacin-induced gastric mucosal injury on 24-h intragastric acidity and plasma gastrin concentration in healthy volunteers // Aliment. Pharmacol. Ther. 1995. — Vol. 9, N 6. — P. 625−631.
- Rainsford K.D. Gastrointestinal adaptation, gastrointestinal injury by NSAIDs. Regulation of eicosanoids and mucosal protection from NSADDs. Kluwer Academic Publishers. 1997. — P. 197−205.
- Rampal P., Martin C., Marquis P. et al. A quality of life study in five hundred and eighty-one duodenal ulcer patients // Scand. J. Gastroenterol. -1994.-Vol. 29.-P. 44−51.
- Ray W.A., Stein C.M., Daugherty J.R. et al. COX-2 selective nonsteroidal anti-inflammatory drugs and risk of serious coronary heart disease. // Lancet. 2002. — Vol. 360. — P. 1071−3.
- Reddy S.T., Herschman H.R. Ligand-induced prostaglandin synthesis requires expression of the TIS 10/PGS-2 prostaglandin synthase gene in murine fibroblasts and macrophages // J. Biol. Chem. 1994. — Vol. 269. -P. 15 473−15 480.
- Reuter B.K., Asfaha S., Buret A. Exacerbation of inflammation-associated colonic injury in rat through inhibition of cyclooxygenase-2. // J. Clin. Invest. 1996. — Vol. 98, N 9. — P. 2076−2085.
- Richy F., Bruyere O., Ethgen O. et al. Time-dependent risk of gastrointestinal complications induced by non-steroidal anti-inflammatory drug use: a consensus statement using a meta-analytic approach // Ann. Rheum. Dis. 2004. — Vol. 63. — P. 759−766.
- Robert A., Nezamis J.E., Phillips J.P. Effect of prostaglandin El on gastric secretion and ulcer formation in the rat // Gastroenterology. 1968. -Vol. 55.-P.481−7.
- Robert A., Nezamis J.E., Phillips J.P. Inhibition of gastric secretion by prostaglandin. // Am. Dig. Dis. 1967. — Vol. 12. — P. 1073- 6.
- Robinson M. New-generation proton pump inhibitors: overcoming the limitations of early-generation agents. // Eur. J. Gastroenterol. Hepatol. -2001. Vol. 13, Suppl. 1. — S43−7.
- Roddam P.L., Rollinson S., Kane E. et al. Poor metabolizers at the cytochrome P450 2D6 and 2C19 loci are at increased risk of developing adult acute leukaemia. // Pharmacogenetics. 2000. — Vol. 10, N 7. — P. 605−15.
- Roh H.K., Dahl M.L., Johansson I., Ingelman-Sundberg M., Cha Y.N., Bertilsson L. Debrisoquine and S-mephenytoin hydroxylation phenotypes and genotypes in a Korean population. // Pharmacogenetics. -1996.-Vol. 6, N5.-P. 441−7.
- Roh H.K., Dahl M.L., Tybring G., Yamada H. // Pharmacogenetics. -1996.-Vol. 6, N6.-P. 547−51.
- Romano M., Lesch C.A., Meise K.S. Increased gastroduodenal concentrations of transforming growth factor in adaptation to aspirin in monkeys and rats. // Gastroenterology. 1996. — Vol. 110. — P. 14 461 455.
- Romano M., Tuccillo C., Santangelo M. Increased COX-2, but not COX-1, mRNA expression in Helicobacter pylori gastritis. // Gut. 1999. -Vol. 45, Suppl. V.-A 25.
- Romkes M., Faletto M.B., Blaisdell J.A., Raucy J.L., Goldstein J.A. Cloning and expression of complementary DNAs for multiple members of the human cytochrome P450IIC subfamily. // Biochemistry. 1991. — Vol. 30, N13.-P. 3247−55.
- Rowe P. H., Starlinger M.U., Kasdon E. Parental aspirin and sodium salicylate area aqually injurious to the rat gastric mucosa. // Gastroenterology. 1987. — Vol. 93. — P. 863−867.
- Roy H.K. Selective Inhibition of COX 2 Too Good To Be True? // Gastroenterology. — 1998. — Vol. 93, N 11. — P. 2019−2020.
- Saitoh T., Fukushima Y., Otsuka H. et al. Effects of rabeprazole, lansoprazole and omeprazole on intragastric pH in CYP2C19 extensive metabolizers. // Aliment. Pharmacol. Ther. 2002. — Vol. 16, N 10. — P. 1811−7.
- Sakamoto C. Roles of COX-1 and COX-2 in gastrointestinal pathophysiology // J. Gastroenterol. 1998. — Vol. 33. — P. 618−24.
- Sanders K.M. Role of prostaglandins in regulating gastric motility // Am. J. Physiol. 1984. — Vol. 247(2 Pt 1). — P. G117−126.
- Sant S.M., Cahill R.J., Gilvany J., CMorain C.A. Do non-steroidal anti-inflammatory drugs have an effect on gastric cell turnover? // Aliment. Pharmacol. Ther. 1995. — Vol. 9, N 5. — P.575−9.
- Santolaria S., Lanas A., Benito R. Helicobacter pylori infection is a protective factor for bleeding gastric ulcers but not for bleeding duodenal ulcers in NSAID users // Aliment. Pharmacol. Ther. 1999. — Vol. 13, N 11.-P. 1511−18.
- Sanz E.J., Villen T., Aim C., Bertilsson L. S-mephenytoin hydroxylation phenotypes in a Swedish population determined after coadministration with debrisoquin // Clin. Pharmacol. Ther. 1989. — Vol. 45, N5.-P. 495−9.
- Sapone A., Vaira D., Trespidi S. et al. The clinical role of cytochrome p450 genotypes in Helicobacter pylori management. // Am.J.Gastroenterol. 2003. — Vol. 98, N 5. — P. 1010−5.
- Sata F., Sapone A., Elizondo G. et al. CYP3A4 allelic variants with amino acid substitutions in exons 7 and 12: evidence for an allelic variant with altered catalytic activity. // Clin. Pharmacol. Ther. 2000. — Vol. 67, Nl.-P. 48−56.
- Sato H., Kitamura T. Prescribing non-steroidal anti-inflammatory drugs together with antisecretory agents is safe, but may be useless. // Gastroenterology. -1996. Vol. 111. — P. 1143−4.
- Savarino V., Mela G.S., Zentilin P. Effect of one-month treatment with nonsteroidal antiinflammatory drugs on gastric pH of rheumatoid arthritis patients // Dig. Dis. Sci. 1998. — Vol. 43, N 3. — P. 459−463.
- Schmassmann A., Peskar B.M., Stettler C. et al. Effects of inhibition of prostaglandin endoperoxide synthase-2 in chronic gastrointestinal ulcer models in rats // Br. J. Pharmacol. 1998. — Vol. 123. — P. 795−804.
- Schmassmann A., Tarnawski A., Peskar B.M. et al. Influence of acid and angiogenesis on kinetics of gastric ulcer healing in rats: interaction with indomethacin // Am. J. Physiol. 1995. — Vol. 268. — P. G276−85.
- Schoenfeld P. Review article: nonsteroidal anti-inflammatory drug-associated gastrointestinal complications, guidelines for prevention and treatment. // Aliment. Pharmacol. Ther. 1999. — Vol. 13. — P. 1273−1285.
- Schwartz J.B. The influence of sex on pharmacokinetics. // Clin. Pharmacokinet. 2003. — Vol. 42, N 2. — P. 107−21.
- Seager J.M., Hawkey C.J. ABC of the upper gastrointestinal tract: Indigestion and non-steroidal anti-inflammatory drugs // BMJ. 2001. -Vol. 323, N7.-P. 1236−9.
- Seibert K., Lefkowith J., Tripp C. COX-2 inhibitors—is there cause for concern? // Nat. Med. 1999. — Vol. 5, N 6. — P. 621−622.
- Sharma V.K., Leontiadis G.I., Howden C.W. Meta-analysis of randomized controlled trials comparing standard clinical doses of omeprazole and lansoprazole in erosive oesophagitis. // Aliment. Pharmacol. Ther. 2001. — Vol. 15. — P. 227−31.
- Shaw M., Talley N.J., Adlis S. Development of a digestive health status instrument: tests of scaling assumptions, structure and reliability in a primary care population. // Aliment. Pharmacol. Ther. 1998. — Vol. 12, N 11.-P. 1067−78.
- Shea-Donohue P.T., Nompleggi D., Myers L. A comparison of the effects of prostacyclin and the 15(S)-15 methyl analogs of PGE2 and PGF2a on gastric parietal and non-parietal secretion. // Dig. Dis. Sci. -1982.-Vol. 27. P. 17−22.
- Sheng H., Shao J., Kirkland S.C. et al. Inhibition of human colon cancer growth by selective inhibition of cyclooxygenase-2 // J. Clin. Invest. 1997. — Vol. 99. — P. 2254−2259.
- Shirai N. Furuta T. High dose dual PPI/AMPC therapy for the treatment of Helicobacter pylori infection after failure of usual standard triple PPI/AMPC/CAM therapy: CYP2C19 polymorphism // Nippon Rinsho. 2002. — Vol. 60, Suppl. 2. — P. 439−44.
- Shirin H., Moss S.F. Helicobacter pylori induced apoptosis. // Gut. -1998.-Vol. 43.-P. 592−594.
- Shorrock C.J., Prescott R.J., Rees W.D. The effects of indomethacin on gastroduodenal morphology and mucosal pH gradient in the healthy human stomach. // Gastroenterology. 1990. — Vol. 99. — P. 334−9.
- Skeljo MV, Giraud AS, Yeomans ND. Adaptation of rat gastric mucosa to repeated doses of non-salicylate non-steroidal anti-inflammatory drugs. // J. Gastroenterol. Hepatol. 1992. — Vol. 7, N 6. — P. 586−90.
- Slomiany B.L. // Scand. J. Gastroenterol. 1997. — Vol. 32. — P. 638 642.
- Smith A. Nitric oxide-releasing therapeutics reduces gastric toxicity problems // PSTT. 1999. — Vol. 2, No. 5.
- Sonnenberg A., El-Serag H.B. Clinical epidemiology and natural history of gastroesophageal reflux disease. // Yale J. Biol. Med. 1999. -Vol. 72, N2−3.-P. 81−92.
- Sopena F., Lanas A., Sainz R. Esophageal motility and intraesophageal pH patterns in patients with esophagitis and chronic nonsteroidal anti-inflammatoiy drug use I I J. Clin. Gastroenterol. 1998. -Vol. 27, N4. -P.316−320.
- Spechler S.J., Lee E., Ahnen D. et al. Long-term outcome of medical and surgical therapies for gastroesophageal reflux disease: follow-up of a randomized controlled trial // JAMA. 2001. — Vol. 285. — P. 2331−2338.
- St. John D.J., Yeomans N.D., McDermott F.T., De Boer W.G. Adaptation of the gastric mucosa to repeated administration of aspirin in the rat // Am. J. Dig. Dis. 1973. — Vol. 18, N 10. — P. 881−5.
- Stack W.A., Hawkey G.M., Atherton J.C. Interaction of risk factors for peptic ulcer bleeding. // Gastroenterology. 1999. — Vol. 116 (4 part 2) -P. A97.
- Stadler P., Armstrong D., Margalith D. et al. Diclofenac delays healing of gastroduodenal mucosal lesions. Double-blind, placebo-controlled endoscopic study in healthy volunteers. // Dig Dis Sci. 1991. -Vol. 36, N5.-P. 594−600.
- Stanghellini V., Tosetti C., Barbara G. Management of dyspeptic patients by general practitioners and specialist // Gut. 1998. — Vol. 43, N 1. — P.21−23.
- Stendal C. Practical guide to gastrointestinal function testing. Blackwell Science. 1997. — 280 p.
- Stewart W.F., Kawas C., Corrada M. et al. Risk of Alzheimer’s disease and duration of NSAID use // Neurology. 1997. — Vol. 48. — P. 626−32.
- Stolte M., Panayiotou S., Schmitz J. Can NSAID/ASA-induced erosions of the gastric mucosa be identified at histology? // Pathol. Res. Pract. 1999. — Vol. 195, N 3. — P. 137−142.
- Sun W.H., Tsuji S., Tsuji M. Cyclooxygenase-2 inhibitors suppress epithelial cell kinetics and delay gastric wound healing in rats // J. Gastroenterol. Hepatol. 1999. — Vol. 15, N 7. — P. 752−761.
- Sviri S, Shpizen S., Leitersdorf E., Levy M., Caraco Y. Phenotypic-genotypic analysis of CYP2C19 in the Jewish Israeli population// Clin Pharmacol Ther. 1999. — Vol. 65, N 3. — P. 275−82.
- Szabo S., Spill W.F., Rainsford K.D. Non-steroidal anti-inflammatory druginduced gastropathy. // Med. Tox. Adverse Drug ExP. 1989. — Vol. 4.-P. 77−94.
- Taha A.S., Dahill S., Sturrock R.D., Lee F.D. Predicting NSAID related ulcers- assessment of clinical and pathological risk factors and importance of differences in NSAID. // Gut. Vol. 35. — P. 891−895.
- Takakubo F., Kuwano A., Kondo I. Evidence that poor metabolizers of (S)-mephenytoin could be identified by haplotypes of CYP2C19 in Japanese. // Pharmacogenetics. 1996. — Vol. 6, N 3. — P. 265−7.
- Takeda K., Kaisho T., Akira S. Toll-like receptors. // Annu. Rev. Immunol. 2003. — Vol. 21. — P. 335.
- Takeuchi K., Ueki S., Okabe S. Importance of gastric motility in the pathogenesis of indomethacin-induced gastric lesions in rats. // Dig. Dis. Sci. 1986. — Vol. 31, N 10. — P. 1114−22.
- Talley N.J., Evans J.M., Fleming K.C. Non-steroidal antiinflammatory drugs and dyspepsia in the elderly. // Dig. Dis. Sci. 1995. -Vol. 40, N6.-P. 1345−1350.
- Talley N.J., Weaver A.L., Zinsmeister A.R. Smoking, alcohol, and nonsteroidal anti-inflammatory drugs in outpatients with functional dyspepsia and among dyspepsia subgroups // Am. J. Gastroenterol. 1994. -Vol. 89, N4.-P. 524−8.
- Talley NJ. Helicobacter pylori and dyspepsia. // Yale J. Biol. Med. -1999.-Vol. 72, N2−3.-P. 145−51.
- Tamminga W.J., Werner J., Oosterhuis B. et al. CYP2D6 and CYP2C19 activity in a large population of Dutch healthy volunteers: indications for oral contraceptive-related gender differences. // Eur. J. Clin. Pharmacol. 1999. — Vol. 55, N 3. — P. 177−84.
- Tanaka A., Araki H., Hase S. Up-regulation of COX-2 by inhibition of COX-1 in the rat: a key to NSAID-induced gastric injury // Aliment. Pharmacol. Ther. 2002. — Vol. 16, N Suppl. 2. — P. 90−101.
- Tanigawara Y., Aoyama N., Kita T., Shirakawa K., Komada F., Kasuga M., Okumura K. CYP2C19 genotype-related efficacy of omeprazole for the treatment of infection caused by Helicobacter pylori // Clin Pharmacol Ther. 1999. — Vol. 66, N 5. — P. 528−34.
- Tarnawski A., Hollander D., Gergely H. Protection of the gastric mucosa by linoleic acid a nutrient essential fatty acid. // Clin. Invest. Med. — 1987. — Vol. 10, N 3. — P. 132−135.
- Tarnawski A., Hollander D., Stachura J. Protection of the rat gastric mucosa against aspirin injury by arachidonic acid: a dietary prostaglandin precursor fatty acid. // Eur. J. Clin. Invest. 1989. — V ol. 19, N3. — P. 278 290.
- Tassaneeyakul W, Tawalee A, Tassaneeyakul W, Kukongviriyapan V, Blaisdell J, Goldstein JA, Gaysornsiri D. Analysis of the CYP2C19 polymorphism in a North-eastern Thai population. // Pharmacogenetics. 2002.-Vol. 12, N3.-P. 221−5.
- Thillainayagam A.V., Tabaqchali S., Warrington S.J. Interrelationships between Helicobacter pylori infection, NSAIDs and gastroduodenal disease: a prospective study in healthy volunteers. // Dig. Dis. Sci. 1994. — Vol. 39. — P.1085−1089.
- Tsuneoka Y., Fukushima K., Matsuo Y., Ichikawa Y., Watanabe Y. Genotype analysis of the CYP2C19 gene in the Japanese population. // Life Sci. 1996. — Vol. 59, N 20. — P. 1711−5.
- Uribe A. Indomethacin inhibits cell proliferation in the oxyntic epithelium of the rat. // Prostaglandins. 1993. — Vol. 45, N 1. — P. 15−26.
- Uribe A., Alam M., Soderman C. Cell kinetic events in early indomethacininduced gastrointestinal ulcerations in the rat. // Eur. J. Gastroenterol. Hepatol. 1997. — Vol. 9, N 3. — P.267−273.
- Uribe A., Alam M., Winell-Kapraali M. Indomethacin inhibits cell proliferation and increases cell losses in rat gastrointestinal epithelium. // Dig. Dis. Sci. 1995. Vol. 40, N 11. — P. 2490−2494.
- Vane J.R., Botting R.M. Mechanism of action of non-steroidal antiinflammatory drugs. // Amer. J. Med. 1998. — Vol. 104, N 3A. — P. 62S-63S.
- Vermes I., Haanen C. Apoptosis and programmed cell death in health and disease. // Adv. Clin. Chem. 1994. — Vol. 31. — P. 177−246,
- Visick A.H. Measured radical gastrectomy // Lancet. 1948. — Vol. 10.-P. 551−5.
- Vivian E.M., Thompson M.A. Pharmacologic strategies for treating gastroesophageal reflux disease. // Clin. Ther. 2002. — Vol. 22. — P. 654 672.
- Voutilainen M., Mantynen T., Farkkila M. Impact of non-steroidal antiinflammatory drug and aspirin use on the prevalence of dyspepsia and uncomplicated peptic ulcer disease // Scand. J. Gastroenterol. 2001. -Vol. 36, N8.-P. 817−21.
- Wagner S., Beil W., Westermann J., Logan R.P. Regulation of gastric epithelial cell growth by Helicobacter pylori: evidence for a major role of apoptosis. // Gastroenterology. 1997. — Vol. 13, N 6. — P. 1836−47.
- Wallace J.L., Bak A., McKindht W. Cyclooxygenase-1 contributes to inflammatory response in rats and mice: Implications for gastrointestinal toxicity.// Gastroenterology. 1998. — Vol. 115. — P. 101−109
- Wallace J.L., McKnight W., Reuter B.K., Vergnolle N. NSAID-induced gastric damage in rats: requirement for inhibition of bothcyclooxygenase 1 and 2. // Gastroenterology. 2000. — Vol. 119, N 3. — P. 706−14.
- Wallace J.L., McKnight W., Wilson T.L. Reduction of shock-induced gastric damage by a nitric oxide-releasing aspirin derivative: role of neutrophils. // Am. J. Pysiol. 1997. — Vol. 273(6) Pt L — P. G1246−51.
- Wallace J.L., Granger D.N. The cellular and molecular basis of gastric mucosal defense // FASEB J. 1996. — Vol. 10, N 7. — P. 731−40.
- Wallace J.L., McKnight W., Miyasaka M. et al. Role of endothelial adhesion molecules in NSAID-induced gastric mucosal injury. // Am. J. Physiol. 1993. — Vol. 265. — P. G993−8.
- Wallace J.L., McKnight W., Reuter B.K. et al. NSAID-induced gastric damage in rats: requirement for inhibition of both cyclooxygenase 1 and 2. // Gastroenterology. 2000. — Vol. 119. — P. 706−14.
- Wan J., Xia H., He N. et al. The elimination of diazepam in Chinese subjects is dependent on the mephenytoin oxidation phenotype. // Br. J. Clin. Pharmacol. 1996. — Vol. 42, N 4. — P. 471−4.
- Wanwimolruk S., Bhawan S., Coville P.F. et al. Genetic polymorphism of debrisoquine (CYP2D6) and proguanil (CYP2C19) in South Pacific Polynesian populations. // Eur. J. Clin. Pharmacol. 1998. -Vol. 54, N5.-P. 431−5.
- Ware J.E. The status of health assessment, 1994. // Annals of Public Health. 1995. — Vol. 16. — P.327−354.
- Ware J.E., Kosinski M. SF-36 Health Survey Version 2.0. Technical Note, Boston, Health Assessment Lab. 1996.
- Ware J.E., Snow K.K., Kosinski M. and Gandek B. SF-36 Health Survey: Manual and interpretation guide. Lincoln, RI: Quality Metric Inc. -2000.
- Ware J.E., Snow K.K., Kosinski M., SF-36 Health Survey Manual and Interpretation Guide. Boston, The Health Institute, New England Medical Center. -1993.
- Warner T.D. et al. Non-steroidal drug selectivities for cyclooxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis // Proc. Natl. Acad. Sci. USA. 1999. — Vol. 96. — P. 7563−68.
- Warren J.R., Marshall B.J. Unidentified curved bacilli on gastric epithelium in active chronic gastritis. // Lancet. 1983. — Vol. 323. — P. 1273−75.
- Wedlund P.J. The CYP2C19 enzyme polymorphism. // Pharmacology. -2000.-Vol. 61.-P. 174−83.
- Weil J., Langman M.J.S., Wainwright H. Peptic ulcer bleeding: accessoiy risk factors and interactions with non-steroidal antiinflammatory drugs // Gut. 2000. — Vol. 46. — P.27−31.
- Weinshilboum R. Inheritance and Drug Response // NEJM. 2003. -Vol. 348.-P. 6.
- Whelton A., Fort J.G., Puma J.A. et al. Cyclooxygenase-2-specific inhibitors and cardiorenal function: a randomized, controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients. // Am. J. Ther. 2001. Vol. 8. — P. 85−95.
- Whittle B.J.R. Protective mechanisms of the gastric mucosa. In: Gustsavsson S., Kumar D., Graham D. Y, eds. The stomach. Edinburgh: Churchill Livingstone. — 1992. — P. 81−101.
- Whittle B.J.R., Vane J.R. Prostanoids as regulators of gastrointestinal function. In: Johnson L.R., Christiansen I, Jackson M.I., Jacobson E.D., Walsh J.H., editors. Physiology of the gastrointestinal tract. New York: Raven.-1987.-P.143−80.
- WHO Adverse Reaction Terminology list, 1991 (www.who.org)
- Wilhelmsen I. Quality of life in upper gastrointestinal disorders // Scand. J.Gastroenterol. 1995. — Vol 211. — P.21−25.
- Willis P., Lynch D.A.F., Prescott R., Lamonby S. Cell proliferation in the postsurgical stomach, dietary salt, and the effect of H. pylori eradication // J. Clin. Pathol. 1999. — Vol. 52. — P.665−669.
- Wong W.M., Wright N.A. Cell proliferation in gastrointestinal mucosa // J. Clin. Pathol. 1999. — Vol. 52. — P.321−333.
- Wright N.A., Goodlad R.A. Measurement of morphokinetic status in experiments on intestinal adaptation // Gut. 1996. — Vol. 38, N 3. — P. 474−5.
- Wrighton S. A, Stevens J.C., Becker G.W. et al. Isolation and characterization of human liver cytochrome P450 2C19: correlation between 2C19 and S-mephenytoin 4'-hydroxylation. // Arch. Biochem. Biophys. 1993. — Vol. 306, N 1. — P. 240−5.
- Xie H.G., Huang S.L., Xu Z.H. et al. Evidence for the effect of gender on activity of (S)-mephenytoin 4'-hydroxylase (CYP2C19) in a Chinese population. // Pharmacogenetics. 1997. — Vol. 7, N 2. — P. 115−9.
- Xie H. G, Kim R. B, Stein C.M. et al. Genetic polymorphism of (S)-mephenytoin 4'-hydroxylation in populations of African descent. // Br. J. Clin. Pharmacol. 1999. — Vol. 48, N 3. — P. 402−8.
- Xie H.G. Genetic variations of S-mephenytoin 4-hydroxylase (CYP2C19) in the Chinese population. // Life Sci. 2000. — Vol. 66, N 14. — P. PL175−81.
- Yacavone R.F., Locke G.R. 3rd, Provenzale D.T., Eisen G.M. Quality of life measurement in gastroenterology: what is available? // Am. J. Gastroenterol. 2001. — Vol. 96, N 2. — P. 285−97.
- Yao T.W., Zeng S., Wang T.W. et al. Phenotype analysis of cytochrome P450 2C19 in Chinese subjects with mephenytoin S/R enantiomeric ratio in urine measured by chiral GC. // Biomed. Chromatogr. -2001.-Vol. 15, N1.-P. 9−13.
- Yeomans N.D. New data on healing of non-steroidal antiinflammatory drug-associated ulcers and erosions. Omeprazole NSAID Steering Committee // Am. J. Med. 1998. — Vol. 104, N3A. — P. 56S-61S.
- Zhu G.H., Wong B.C., Eggo M.C. Non-steroidal anti-inflammatory drug-induced apoptosis in gastric cancer cells is blocked by protein kinase C activation through inhibition of c-myc // Br. J. Cancer. 1999. — Vol. 79.-P. 393−400.
- Zhu G.H., Yang X.L., Lai K.C. Non-steroidal anti-inflammatory drugs could reverse Helicobacter pylori-induced apoptosis and proliferation in gastric epithelial cells // Dig. Dis. Sci. 1998. — Vol. 43. — P. 1957−1963.